Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma

Clinical Trial ID NCT01216826

PubWeight™ 7.38‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01216826

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol 2013 0.95
2 Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy. Paediatr Drugs 2015 0.86
3 Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin 2014 0.86
4 Targeted therapies for bone sarcomas. Bonekey Rep 2013 0.85
5 Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma. Int J Mol Sci 2016 0.82
6 Bone sarcomas: from biology to targeted therapies. Sarcoma 2012 0.82
7 Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int 2016 0.81
8 Advances in paediatric cancer treatment. Transl Pediatr 2014 0.76
9 The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy. Front Oncol 2015 0.76
Next 100